Molecular Pathogenesis Group
Head of laboratory:
The Molecular Pathogenesis Group of the Multiple Myeloma Research Unit is involved in the examination of genetic factors in the causation and control of disease behaviour in myeloma, one of the common haematological malignancies. So far this group has established a relationship between the presence of chromosomal translocations in the immunoglobulin genes and clinical behaviour, and is currently investigating the impact of specific chromosomal partners and the dysregulation of oncogenes. Furthermore, this group is currently studying the effect of a translocation t(4;14) in multiple myeloma treated by thalidomide. This research represents a major component of laboratory studies being conducted as part of the National Myeloma Trial under the Australian Leukemia and Lymphoma Study Group (ALLG).
In addition, we are interested in elucidating the causes to myeloma drug resistance, especially with the emerging novel biological agents such as the proteosome inhibitors and immunomodulatory drugs. In collaboration with Dr John Allen of the Centenary Institute, we are initiating studies in the effect of XBP-1 in myeloma drug resistance, both to chemotherapy such as 'conventional' steroids and alkylating agents, and specifically in relation to resistance to proteasome inhibitors.
A new but related area of study is in the impact and mechanisms of myeloma drug resistance in autologous stem cell transplantation in myeloma. A dose escalation study using high dose melphalan is being performed through the ALLG, and we will be studying the effect of XBP-1 related drug resistance on the efficacy of escalating doses in autologous transplant.
